© 2026 Dr. Reuter Investor Relations. Article written by Sabine Lembert. All rights reserved.
Stem cells are among the great medical hopes for various therapies. This is because they have the unique ability to develop into different cell types and to renew themselves. Stem cell therapy is therefore a treatment approach that uses the body’s own or foreign stem cells to repair or regenerate damaged tissue. Examples include dermatology and pain therapy. This is where the biotech company NurExone Biologic Inc (WKN: A3DNSU, ISIN: CA67059R1091) comes into play: Exo-Top Inc., NurExone’s US subsidiary, will start producing standardized exosomes from stem cells for use in its own therapeutic applications as carriers for siRNA or small molecules and for use in supply of naïve exosomes for aesthetic or non-medical applications. Therapies, such as those offered by the flagship product ExoPTEN, are already showing promising results in preclinical studies with first-in-human targeted at 2026. For therapeutic applications, all necessary steps required by the FDA must be completed before market launch. However, the new stem cell law in Florida (SB-1768) could now offer a strategic advantage for naïve (unloaded) exosomes for certain applications.
This article is being disseminated on behalf of Dr. Reuter Investor Relations, a third-party issuer and is intended for informational purposes only.
Florida allows doctors to use stem cell therapy
As early as July 1, 2025, the use of non-FDA-approved stem cell therapies is likely to be relaxed in the US state of Florida. SB-1768 stipulates that doctors are permitted to use stem cells under strict conditions. At least if they are within the scope of their work and focus on orthopedics, wound care, or pain therapy, whereby strict requirements apply to ensure patient safety and ethical standards.
US subsidiary ExoTop could benefit from stem cell law
For ExoTop – the US subsidiary of NurExone Biologic Inc. – SB-1768 is likely to be a strategic advantage, as the company will be producing potent, well-characterized exosomes from human mesenchymal stem cells. The company is establishing its own GMP (Good Manufacturing Practice)-compliant production capacities for these exosomes for its own use and for B2B supply. The new legal situation thus creates early market access, accelerates potential revenue streams, and could position ExoTop as a first mover in a market with high demand – for example, in pain therapy, dermatology, or wound healing.
Other players are also preparing for the new regulatory environment in Florida. For example, the biotech company ZEO ScientifiX Inc. (WKN: A3E4PZ, ISIN: US98980W1045) has launched an educational initiative for physicians called the ZEO Masterclass. The training is intended to prepare medical professionals for the implementation of SB-1768.
Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.